BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: 2024 Wells Fargo Healthcare Conference in Boston, MA Wednesday, September 4, 2024, at 10:15 a.m. Eastern Time Morgan Stanley 22nd Annual Global Healthcare Conference in New... Read more
Asia’s first 1.2 GHz NMR system empowers researchers to advance scientific discoveries SEOUL, South Korea–(BUSINESS WIRE)– Bruker Corporation is pleased to announce the successful installation and acceptance of a 1.2 GHz Avance® Nuclear Magnetic Resonance (NMR) spectrometer at the Korea Basic Science Institute ( KBSI ), just in time before the start of the ICMRBS... Read more
BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on September 16, 2024 to stockholders of record as of September 2, 2024. About Bruker Corporation... Read more
NovAliX is a drug discovery focused CRO with award-winning chemistry teams and one of the world’s most comprehensive biophysics platforms. Bruker and NovAliX intend to collaborate on enabling new paradigms in drug discovery, leveraging advanced biophysical methods, and NMR in particular, to structural, binding and functional characterization. STRASBOURG, France–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today... Read more
Q2 2024 revenues of $800.7 million, up 17.4% year-over-year (yoy); organic revenue up 7.4% yoy; CER revenue up 18.5% yoy Q2 2024 GAAP EPS $0.05; non-GAAP EPS $0.52, up 4.0% yoy Bruker increases FY 2024 revenue guidance to $3.38-$3.44 billion, now including the NanoString business; implies revenue growth of 14% to 16%, and organic revenue... Read more
Bruker Announces Date and Time of Second Quarter 2024 Earnings Release and Webcast BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2024 financial results before market opening on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the... Read more
WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2024. Second Quarter 2024 Highlights Second quarter revenue was $10.54 billion. Second quarter GAAP diluted earnings per share (EPS) increased 15% to $4.04. Second quarter adjusted EPS increased... Read more
WASHINGTON, July 23, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the quarter ended June 28, 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Second Quarter 2024 Results Net earnings were $907 million, or $1.22 per diluted common share and non-GAAP adjusted diluted net... Read more
Bruker Announces that Injunction Impacting NanoString’s CosMx Spatial Molecular Imager Products in Germany Has Been Suspended Effective Immediately The patent at issue was ruled invalid by the German Federal Patent Court in May 2024 BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced that it has posted a bond, as authorized by the Munich Higher... Read more
Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics. Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together... Read more